World Lifestyler
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
  • Art & Culture
    • Architecture
    • Art & Exhibitions
    • Books
    • Design
    • Film & Music
  • Competitions
    • Dining Experiences
    • Hotel Stays
    • Luxury Experiences
    • Product Giveaways
    • Reader Exclusives
    • Travel Giveaways
  • Food & Drink
    • Chefs
    • Coffee Culture
    • Food Destinations
    • Recipes
    • Restaurants
    • Wine & Spirits
  • Lifestyle
    • Design
    • Fashion
    • Health & Wellbeing
    • Homes & Property
    • Love & Romance
  • People
    • Creatives
    • Entrepreneurs
    • Icons
    • Interviews
    • Profiles
    • Rising Talent
  • Travel
    • Adventure & Experience Travel
    • City Guides
    • Destinations
    • Hotels
    • Secret Spots
    • Travel Trends
No Result
View All Result
WORLD LIFESTYLER
No Result
View All Result
Home Press Releases Press Releases - Lifestyle

Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®

Cision PR Newswire by Cision PR Newswire
May 1, 2026
in Press Releases - Lifestyle
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

TORONTO, May 1, 2026 /PRNewswire/ – Apotex Inc. (“Apotex” or the “Company”), Canada’s largest Canadian‑based global health company, today announced that Health Canada has approved Apo‑Semaglutide InjectionTM, a generic equivalent of Ozempic® (semaglutide injection). As the first Canadian‑based pharmaceutical company to gain authorization for a generic equivalent of Ozempic®, this approval reinforces Apotex’s leadership in bringing high‑quality, affordable alternatives to Canadians and reflects the Company’s long‑standing commitment to strengthening access to essential medicines across the country. Apo-Semaglutide Injection will be the first Canadian generic equivalent to offer both the 2 mg/pen (0.68mg/mL) and 4 mg/pen (1.34 mg/mL) pen formats commercially, aligning with all brand equivalent SKUs.


Apotex Inc. Logo (CNW Group/Apotex Inc.)

Developed in partnership with Orbicular Pharmaceutical Technologies, Apo‑Semaglutide Injection has undergone Health Canada’s standard regulatory review for peptide medicines.

The authorization includes two prefilled pen formats:

  • A pen delivering 0.25 mg or 0.5 mg doses (containing 2 mg of semaglutide 0.68mg/mL)
  • A pen delivering 1 mg doses (containing 4 mg of semaglutide 1.34 mg/mL)

In Canada, Apo‑Semaglutide Injection (semaglutide injection) is indicated for the once‑weekly treatment of adults with type 2 diabetes mellitus to improve glycemic control, in combination with diet and exercise. 1

For more than 50 years, Apotex has played a central role in supporting the sustainability of Canada’s healthcare system. The Company’s medicines have generated significant savings for public and private drug plans, helping expand access to essential treatments.

“This approval reflects our Canadian roots and our commitment to improving access to medicines,” said Martin Arès, President, Apotex Canada and Rest of World (ROW). “As a Canadian‑based global health company, we are proud to bring forward a high‑quality, affordable alternative that supports patients, prescribers, and the long‑term sustainability of our healthcare system. We look forward to bringing this product to market in the very near future.”

“We are pleased to collaborate with Apotex on this important program,” said Dr. M. S. Mohan, Managing Director, Orbicular Pharmaceutical Technologies. “The approval of Apo‑Semaglutide Injection demonstrates the strength of our peptide development platform and the disciplined scientific work undertaken by both teams to meet Health Canada’s rigorous expectations.”

Apotex remains focused on advancing trusted, high‑quality generic medicines that enhance patient access and contribute to a resilient Canadian healthcare landscape.

Healthcare professionals should consult the complete for detailed information on warnings, precautions, adverse reactions, and patient monitoring requirements.

About Apotex

Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.

Learn more at www.apotex.com.

1 Product Monograph: https://health-products.canada.ca/dpd-bdpp/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/apotex-becomes-the-first-canadianbased-pharmaceutical-company-to-receive-health-canada-approval-for-a-generic-equivalent-of-ozempic-302760415.html

SOURCE Apotex Inc.

Cision PR Newswire

Cision PR Newswire

Related Posts

The One Where SHEGLAM Meets FRIENDS

October 26, 2026

Rapidus and HCLTech announce partnership for next-generation semiconductor technologies

October 26, 2026

Parloa’s Agent Management Platform now sold as an SAP Solution Extension for agentic customer interactions

October 26, 2026

Temu Partners with Spain’s Recyclia to Support Seller Extended Producer Responsibility

October 26, 2026

SUNON Brings AI, Nature and Human-Centered Design to ORGATEC 2026

October 26, 2026

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

October 26, 2026

Popular News

  • Banks must move from managing climate risk to financing resilience, new COP31 paper argues

    0 shares
    Share 0 Tweet 0
  • Happiest Minds’ Arttha deployed Spark by Absa at Mauritius for Digital Banking Services

    0 shares
    Share 0 Tweet 0
  • Zetexa Brings Its Fintel API to Singapore FinTech Festival 2026

    0 shares
    Share 0 Tweet 0
  • LGT Middle East named Best Pure Play Private Bank at the WealthBriefing MENA Awards 2026

    0 shares
    Share 0 Tweet 0
  • Dubai International Chamber opens representative office in Miami to strengthen trade and investment ties between Dubai and the United States

    0 shares
    Share 0 Tweet 0

About & Contact

  • About Us
  • Branding Style Guide
  • Contact Us
  • Help Centre
  • Media Kit
  • Site Map

Explore Content

  • Events
  • Newsletter
  • Press Releases
  • Topics

Legal & Privacy

  • Advertiser & Partner Policy
  • Communications & Newsletter Policy
  • Contributor Agreement
  • Copyright Policy
  • Privacy Policy
  • Prohibited Content Policy
  • Terms of Service

Tiny Media Brands

  • Silicon Valleys Journal
  • The AI Journal
  • The City Banker
  • The Wall Street Banker
  • World Lifestyler

© 2025 World Lifestyler

No Result
View All Result
  • Home

© 2025 World Lifestyler